Amazon is hiring a data scientist for its benefits team, according to a new job post. The person will work closely with the joint venture between Amazon, Berkshire Hathaway and JP Morgan, led by Atul Gawande. » Read More
UnitedHealth, the largest U.S. health insurer, reported better-than-expected third-quarter earnings and revenue on Tuesday. » Read More
By: Angelica LaVito
Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged. » Read More
By: Christina Farr
Twitter's Jack Dorsey has an idea about how to fix the filter bubble problem. » Read More
This year's Upstart 100 list represents nearly every sector of the economy, from enterprise software and finance to insurance, health care and retail. And they have all risen quickly to become entrepreneurial success stories worth keeping an eye on.
There are hundreds of companies around the world with the potential to become acquisition targets, unicorns or public companies. CNBC's second annual list of promising young start-ups highlights the ones to keep an eye on.
Heartbeat, a medical start-up, is opening up new clinics across Manhattan
A man drank too much of an erectile dysfunction drug purchased over the internet and it tinted his vision red, USA Today reports. Doctors have been unable to fix it.
The first week of October saw an array of recalls. USA Today has the round-up.
A chemistry professor breaks down why barista-made coffee always tastes better than yours in The Conversation.
Our love for capturing the perfect selfie has introduced a new danger, — selfie deaths, USA Today reports. The most common cause? Drowning.
Guardant Health CEO Helmy Eltoukhy told CNBC on Thursday the company's liquid biopsy, Guardant360, is a "big game changer" when it comes to the detection of cancer.
The Chan Zuckerberg Biohub is investing $14 million into new research areas. One scientist will be studying why coral reefs and their DNA are so resilient, even in extreme circumstances like after nuclear testing.
U.S. District Judge Alison Nathan said the court is required to determine whether the enforcement action is "fair and reasonable, with the additional requirement that the public interest not be disserved."
A North Carolina company is recalling more than 89,000 pounds of ready-to-eat ham products for possible listeria contamination that has led to one death and three illnesses, USA Today reports.
A rare fruit could wind up in U.S. stores in the near future after scientists spliced its DNA to make it heartier and more efficient. It's called the groundcherry, and its success could lead to the modification of more rare fruits and vegetables. USAToday reports.
Walgreens will experiment with adapting Birchbox's concept to some of its stores, stocking shelves with more "prestige" makeup brands, dedicating more floor space to Birchbox and allowing customers to "build your own Birchbox" at Walgreens.
The company filed a complaint with the U.S. International Trade Commission alleging these companies "blatantly emulated the distinctive design" of Juul's system.
A new study found that artificial sweeteners commonly found in low-sugar foods can harm the gut microbial system. US News & World Report has the story.
The way the Kavanaugh hearing was handled by some senators and the White House was evocative did at times look similar to that of early Soviet mock trials, according to a Russian Literature scholar in The Conversation.
The average deductible for a worker in an employer health plan this year is $1,573, up 4.5 percent from $1,505 in 2017, according to new data from the 2018 Kaiser Family Foundation employer health benefits survey.
Testosterone replacement therapy is gaining wider use, but there are potential health risks. These include heart attack and stroke in men over 65 and infertility in young men.
The Food and Drug Administration surprised e-cigarette manufacturer Juul at its San Francisco headquarters last week and seized "thousands of pages of documents" related to the company's marketing practices.
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices, The New York Times reports.